Stock RNA AVIDITY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
27.45 USD -0.07% Intraday chart for Avidity Biosciences, Inc. -6.95% +203.31%
May. 17 Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing MT
May. 15 Transcript : Avidity Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
PR
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
PR
Avidity Biosciences to Participate in Upcoming Investor Conference
PR
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
PR
Avidity Biosciences : April 2024 Corporate Presentation
PU
Avidity Biosciences : (5.7 MB)
PU
Avidity Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
PR
Avidity Biosciences Honors Rare Disease Day
AQ
Avidity Biosciences Honors Rare Disease Day®
PR
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
PR
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
PR
Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
PR
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNA Stock
  4. News Avidity Biosciences, Inc.
  5. Press Releases